Compare WGO & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | SGP |
|---|---|---|
| Founded | 1958 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.5M | 799.4M |
| IPO Year | 1994 | 2026 |
| Metric | WGO | SGP |
|---|---|---|
| Price | $23.48 | $24.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $37.80 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 597.2K | 108.2K |
| Earning Date | 10-21-2026 | 11-10-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | ★ 106.82 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $1,985,674,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | $28.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.13 | $17.06 |
| 52 Week High | $50.16 | $30.56 |
| Indicator | WGO | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 23.92 | 43.31 |
| Support Level | N/A | $24.85 |
| Resistance Level | $30.90 | $26.29 |
| Average True Range (ATR) | 0.84 | 1.43 |
| MACD | -0.20 | -0.37 |
| Stochastic Oscillator | 0.00 | 29.19 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2010 with the acquisition of SunnyBrook and acquired Grand Design in 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in 2019, and acquired Barletta pontoon boats in 2021. It also is developing electric and autonomous technology.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.